Novartis Wraps Zolgensma Price, Availability Negotiations in Canada

Novartis Wraps Zolgensma Price, Availability Negotiations in Canada

309279

Novartis Wraps Zolgensma Price, Availability Negotiations in Canada

Novartis has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding pricing and availability of Zolgensma (onasemnogene abeparvovec), its approved gene therapy for spinal muscular atrophy (SMA), for pediatric patients. With this negotiation completed, individual public drug plans in Canada will now make final decisions about the coverage and availability of Zolgensma for children with SMA, according to the company. “We know the SMA community has been waiting for this day and we’re thrilled that…

You must be logged in to read/download the full post.